CClinicalTrials.gg
Active, not recruitingNCT04766424STITCHUpdated Jun 25, 2024

Sleep Technology Intervention to Target Cardiometabolic Health

An interventional study of Sleep extension intervention and Health education in Elevated Blood Pressure and Habitual Sleep Duration of Less Than or Equal to 7 Hours, sponsored by University of Utah. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by University of Utah · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to test the efficacy of a behavioral sleep extension intervention on sleep duration, cardio-metabolic disease risk factors, and health behaviors among adults with elevated blood pressure/hypertension and short sleep duration.

Read the detailed description

Half of U.S. adults have at least one cardio-metabolic disease (CMD), including hypertension (HTN), heart disease, stroke, or diabetes. Even with advances in screening, education, and medication management, controlling these chronic diseases remains challenging. Despite the well-established negative effects of short sleep duration, surprisingly few studies have tested the benefits of sleep extension and even fewer studies evaluate the science of sleep extension interventions. Therefore, the goal of this study is to test the efficacy of a behavioral sleep extension intervention on sleep duration, CMD risk factors, and health behaviors among adults with elevated BP/HTN and short sleep duration.

02

Conditions studied

  • Elevated Blood Pressure
  • Habitual Sleep Duration of Less Than or Equal to 7 Hours

Browse trials for

03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 120 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Utah is the lead sponsor of 969 studies on the registry; 178 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 62 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18-65
  • 24h ABP readings indicating elevated blood pressure (BP) or hypertension (24h average systolic (SBP) of 115-145 mmHg or diastolic (DBP) of 75-90 mmHg). Patients taking antihypertensive medications will be permitted if stable dose for >8 weeks
  • Time in bed \<8 hours and habitual sleep duration \<7 hours via actigraphy;
  • Smartphone user
  • Able to read/write in English.

Exclusion criteria

Exclusion Criteria:

  • High risk or presence of moderate to severe comorbid sleep disorders (i.e., obstructive sleep apnea AHI 15 or greater, restless legs syndrome, or insomnia) as assessed by the questionnaires and overnight obstructive sleep apnea at the baseline/screening
  • Resistant hypertension, defined as >4 antihypertensive medications or taking medications and standardized in lab BP >130 mmHg SBP or 80 mmHg DBP at screening History of cognitive or neurological disorders (e.g. dementia, Parkinson's, Multiple Sclerosis)
  • BMI>50 kg/m2 or arm circumference greater than extra large cuff
  • Presence of major psychiatric disorders (e.g. schizophrenia, bipolar disorder)
  • alcohol abuse on the Audit-C (score >4 for men, >3 for women)
  • drug use on the NIDA-Modified ASSIST (score >3),90
  • moderate to severe depressive symptoms (PHQ-8 >10)
  • Unstable or serious medical illness that would interfere with participation (cancer, renal disease on dialysis)
  • Overnight work more than 1x per month
  • Use of hypnotic or stimulant medications
  • Situations that would significantly impact the ability to extend sleep, including overnight caregiving responsibility for children under the age 1, elderly or disabled adults >1x per week
  • Inability to read or write in English
  • Pregnancy/desire to become pregnant during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Behavioral sleep extension group

    Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.

    Behavioral: Sleep extension intervention

  • Other
    Health education

    Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.

    Behavioral: Health education

Interventions

  • BehavioralSleep extension intervention

    Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.

  • BehavioralHealth education

    Participants will receive 8 weekly health education newsletters delivered via email.

06

What researchers measure

Primary outcomes

  1. Sleep duration

    Sleep duration will be measured using wrist actigraphy for 7 days

    Time frame: 8 weeks

Secondary outcomes

  1. 24 hour ambulatory blood pressure

    Ambulatory blood pressure glycemic control, lipids).

    Time frame: 8 weeks

  2. 24 hour ambulatory blood pressure

    Ambulatory blood pressure glycemic control, lipids).

    Time frame: 12 months

  3. Sleep duration

    Sleep duration will be measured using wrist actigraphy for 7 days

    Time frame: 12 months

Other outcomes

  1. Diet

    24 hour diet recall

    Time frame: 8 weeks

  2. Diet

    24 hour diet recall

    Time frame: 12 months

  3. Physical activity

    Accelerometer measured activity over 7 days

    Time frame: 8 weeks

  4. Physical activity

    Accelerometer measured activity over 7 days

    Time frame: 12 months

  5. HbA1c

    Cardiometabolic marker

    Time frame: 12 months

  6. C-reactive protein (CRP)

    Cardiometabolic marker

    Time frame: 8 weeks

  7. C-reactive protein (CRP)

    Cardiometabolic marker

    Time frame: 12 months

  8. IL-6

    Cardiometabolic marker

    Time frame: 8 weeks

  9. IL-6

    Cardiometabolic marker

    Time frame: 12 months

07

Study locations

1 site
  • University of Utah
    Salt Lake City, Utah 84108, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data will be made available upon request to the investigators at the end of the study.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04766424
Lead sponsor
University of Utah
Collaborators
University of Illinois at Chicago, National Institute of Nursing Research (NINR)
Responsible party
Kelly Glazer Baron (Professor, University of Utah) — Principal investigator
First posted
Feb 23, 2021
Start date
Mar 30, 2021
Primary completion
Jun 14, 2024
Completion
Jun 14, 2025 (estimated)
Last update
Jun 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion